CVE-2017-8562

Description

Microsoft Windows 8.1 and Windows RT 8.1, Windows Server 2012 and R2, Windows 10 Gold, 1511, 1607, and 1703, and Windows Server 2016 allows an elevation of privilege vulnerability due to Windows improperly handling calls to Advanced Local Procedure Call (ALPC), aka "Windows ALPC Elevation of Privilege Vulnerability".

Category

7.0
CVSS
Severity: High
CVSS 3.0 •
CVSS 2.0 •
EPSS 0.47%
Vendor Advisory microsoft.com
Affected: Microsoft Corporation Microsoft Windows 8.1 and Windows RT 8.1, Windows Server 2012 and R2, Windows 10 Gold, 1511, 1607, and 1703.
Published at:
Updated at:

References

Link Tags
http://www.securityfocus.com/bid/99397 third party advisory vdb entry
https://portal.msrc.microsoft.com/en-us/security-guidance/advisory/CVE-2017-8562 patch vendor advisory

Frequently Asked Questions

What is the severity of CVE-2017-8562?
CVE-2017-8562 has been scored as a high severity vulnerability.
How to fix CVE-2017-8562?
To fix CVE-2017-8562, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2017-8562 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2017-8562 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2017-8562?
CVE-2017-8562 affects Microsoft Corporation Microsoft Windows 8.1 and Windows RT 8.1, Windows Server 2012 and R2, Windows 10 Gold, 1511, 1607, and 1703..
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.